Cargando…

Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world

The evolution of diagnosis and treatment of advanced nonsmall‐cell lung cancer (NSCLC) has led to increasing the use of targeted therapy and immune checkpoint inhibitors. The study goal was to assess the effect of molecular testing and the introduction of new therapies on overall survival (OS). All...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shokoohi, Aria, Al‐Hashami, Zamzam, Moore, Sara, Pender, Alexandra, Wong, Selina K., Wang, Ying, Leung, Bonnie, Wu, Jonn, Ho, Cheryl
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704182/ https://www.ncbi.nlm.nih.gov/pubmed/34786889 http://dx.doi.org/10.1002/cam4.4427

Ejemplares similares

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
por: Leung, Bonnie, et al.
Publicado: (2023)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing
por: Jones, Lauren, et al.
Publicado: (2022)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
por: Rittberg, Rebekah, et al.
Publicado: (2022)

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment
por: Wong, Selina K., et al.
Publicado: (2021)

Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients
por: Moore, Sara, et al.
Publicado: (2020)

Survival Outcomes of Salvage Therapy for Local and Regionally Recurrent NSCLC
por: Moore, Sara, et al.
Publicado: (2020)

Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
por: Denault, Marie-Hélène, et al.
Publicado: (2023)

Digoxin exerts anticancer activity on human nonsmall cell lung cancer cells by blocking PI3K/Akt pathway
por: Wang, Yingying, et al.
Publicado: (2021)

Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases
por: Moyers, Justin T., et al.
Publicado: (2021)

Serum SP70 is a sensitive predictor of chemotherapy response in patients with advanced nonsmall cell lung cancer
por: Liu, Jingping, et al.
Publicado: (2018)

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer
por: Hellmann, Matthew D., et al.
Publicado: (2020)

Disparate outcomes in nonsmall cell lung cancer by immigration status
por: Chau, Brittney, et al.
Publicado: (2021)

Psychosocial Distress Scores and Needs among Newly Diagnosed Sarcoma Patients: A Provincial Experience
por: Srikanthan, Amirrtha, et al.
Publicado: (2019)

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer
por: Yu, Limeng, et al.
Publicado: (2023)

Value of Precision Medicine in Advanced Non‐Small Cell Lung Cancer: Real‐World Outcomes Associated with the Use of Companion Diagnostics
por: John, Ani, et al.
Publicado: (2020)

Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysis
por: Cao, Rui, et al.
Publicado: (2019)

The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman
por: Salman, Bushra, et al.
Publicado: (2023)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Neoadjuvant chemotherapy and Avelumab in early stage resectable nonsmall cell lung cancer
por: Tfayli, Arafat, et al.
Publicado: (2020)

Predictive biomarkers in nonsmall cell carcinoma and their clinico-pathological association
por: Mehta, Anurag, et al.
Publicado: (2019)

A real‐world, population‐based study of patterns of referral, treatment, and outcomes for advanced pancreatic cancer
por: Abdel‐Rahman, Omar, et al.
Publicado: (2018)

Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer
por: Lasalvia-Prisco, Eduardo, et al.
Publicado: (2008)

Real‐world outcomes of advanced melanoma patients not represented in phase III trials
por: van Zeijl, Michiel C. T., et al.
Publicado: (2020)

Nr5a2 promotes cancer stem cell properties and tumorigenesis in nonsmall cell lung cancer by regulating Nanog
por: Ye, Ting, et al.
Publicado: (2019)

Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data
por: Xu, Song, et al.
Publicado: (2020)

A meta‐analysis: microRNAs’ prognostic function in patients with nonsmall cell lung cancer
por: Yu, Na, et al.
Publicado: (2017)

Treatment for Recurrent Differentiated Thyroid Cancer: A Canadian Population Based Experience
por: Shokoohi, Aria, et al.
Publicado: (2020)

Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report
por: Denault, Marie-Hélène, et al.
Publicado: (2022)

Advances in immunotherapy for cervical cancer
por: Grau-Bejar, Juan Francisco, et al.
Publicado: (2023)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Umbilical metastases: Real‐world data shows abysmal outcome
por: Hugen, Niek, et al.
Publicado: (2021)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real‐world evaluation
por: Baker, Hailey A., et al.
Publicado: (2018)

Harnessing neutrophil plasticity for HCC immunotherapy
por: Ramon-Gil, Erik, et al.
Publicado: (2023)

Radio(chemo)therapy in locally advanced nonsmall cell lung cancer
por: Glatzer, Markus, et al.
Publicado: (2016)

Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole‐slide images
por: Ono, Akira, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t1dlbch70rboicdppuni4cahn4